Bill
A 10820
New York bill expanding insurance coverage and access to prescription weight management drugs by reducing prior authorization requirements and cost barriers.
Bill A 10820 would expand access to prescription medications used for chronic weight management in New York by requiring or encouraging insurance coverage and removal of prior authorization barriers. The bill addresses the growing use of GLP-1 receptor agonists (like semaglutide and tirzepatide) for weight loss, which have become significantly more expensive and less accessible than when used for diabetes treatment.
Obesity affects roughly 40% of American adults and contributes to serious health conditions including diabetes, heart disease, and certain cancers. Prescription weight management drugs have shown clinical effectiveness but remain financially inaccessible to many New Yorkers, potentially widening health disparities. This bill could affect insurance premiums, pharmaceutical pricing, and how quickly patients can access these medications.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
